Gsa Capital Partners LLP Seelos Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.66 - $1.22 $31,691 - $58,581	48,018 New	48,018 $57,000
Q4 2022 Feb 13, 2023	SELL	$0.66 - $259.46 $21,262 - $8.36 Million	-32,216 Reduced 23.47%	105,050 $71,000
Q3 2022 Nov 14, 2022	BUY	$0.65 - $278.68 $71,321 - $30.6 Million	109,725 Added 398.41%	137,266 $141,000
Q2 2022 Aug 09, 2022	BUY	$0.51 - $0.93 $14,045 - $25,613	27,541 New	27,541 $19,000
Q4 2021 Feb 14, 2022	SELL	$1.59 - $2.38 $128,786 - $192,775	-80,998 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.69 - $2.89 $136,886 - $234,084	80,998 New	80,998 $195,000
Q1 2021 May 10, 2021	SELL	$1.35 - $4.99 $34,501 - $127,529	-25,557 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$0.74 - $2.01 $1,391 - $3,778	-1,880 Reduced 6.85%	25,557 $40,000
Q3 2020 Nov 06, 2020	BUY	$0.6 - $1.25 $16,462 - $34,296	27,437 New	27,437 $26,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $40.5M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.